TRIAL DETAIL
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 10/01/2016 |
Age of Trial (yrs) 7.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
SDH-directed |
|||
Strategy: |
Radio labeled tracer for GRPR expressing malignancies |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
MITIGATE-NeoBOMB1 |
|||
Sponsor: |
Medical University Innsbruck |
|||
Patient Contact: |
Clemems Decristoforo, Univ.-Doz.Dr
0043512504 ext 80951
clemens.decristoforo@tirol-kliniken.at
Leonhard Gruber, Dr.med.
0043512504 ext 82307
leonhard.gruber@i-med.ac.at
|
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Subcutaneous |
|||
Trial Notes: |
This trial is for diagnostics only. It is not therapeutic. Plans were to conclude the MITIGATE project in the Fall of 2017. The ClinicalTrials.gov trial listing has not been updated since the trial was first listed in October, 2016. We will keep the trial status as 'Recruiting' until we get more information. |
|||
Trial Links |
Trial Results |
Drug Information |
| Advanced Acelerator Applications Pipeline |
| Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Innsbruck |
6020 |
Austria |